Articles tagged "Immunosuppression"

2017 American Transplant Congress
Disease Progression on Neoadjuvant Chemotherapy Is a Strong Predictor of Recurrence for Pediatric Hepatoblastoma.
M. Kueht,¹ S. Commander,¹ T.-A. Ha,¹ A. Rana,^1,2 Y. Shi,¹ S. Vasudevan,^1,2 J. Goss.^1,2
¹Surgery, Baylor College of Medicine, Houston; ²Surgery, Texas Children's Hospital, Houston
Purpose. In addition to peri-operative chemotherapy, proper triage between orthotopic liver transplantation (OLT) and partial hepatectomy (PH) is critical to limiting disease recurrence in pediatric…
2017 American Transplant Congress
Saftey & Long Term Outcomes of Tocilizumab (Anti-IL6R, TCZ) Therapy in Treatment of Chronic Antibody Mediated Rejection (CABMR) & Transplant Glomerulopathy (TG) in Highly-HLA Sensitized (HS) Patients (PTs).
J. Choi,¹ O. Aubert,² A. Vo,¹ A. Loupy,² M. Haas,³ S. Louie,¹ A. Kang,¹ A. Peng,¹ R. Najjar,¹ E. Huang,¹ M. Toyota,⁵ X. Zhang,⁴ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Transplant Group, University Paris Descartes, Paris, France; ³Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA; ⁴Department of HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ⁵Transplant Immunology Lab, Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: DSAs in HS pts lead to poor allograft survival & return to a dialysis. Treatment options for CABMR and TG are limited. IL-6 appears…
2017 American Transplant Congress
Belatacept Conversion in Kidney Recipients with Low GFR Does Not Improve Renal Function.
D. Abdelwahab,¹ S. Byron,² B. Kaplan,¹ R. Heilman.¹
¹Transplant, Mayo Clinic, Scottsdale, AZ; ²Biostatistics and Informatics, Mayo Clinic, Rochester, MN
Background:Belatacept interferes with signal 2 of T cell activation via blockade CD80/86 which doesn't adversely impact renal function. We tested a hypothesis that Belatacept conversion…
2017 American Transplant Congress
Medicinal Herb Cordyceps Sinensis Promotes Long-Term Allograft Survival by Tipping the Balance Between CD4+FoxP3+ Tregs and CD8+ Tcm Cells.
Z. Dai,¹ H. Dai.²
¹Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China; ²University of Pittsburgh, Pittsburgh, PA
Achieving long-term allograft survival or tolerance without continuously global immunosuppression is highly desirable in transplantation. This study was set to induce long-term allograft survival using…
2017 American Transplant Congress
Inhibition of Bruton Tyrosine Kinase Blocks Sensitization in Response to Allogeneic Skin Transplantation and Prolong Skin Graft Survival.
N. Datta, T. Palumbo, J. Kupiec-Weglinski, A. Zarrinpar.
Surgery, University of California, Los Angeles, CA
Antibody mediated rejection and donor specific antibodies are important causes of both early (hyperacute) and late (chronic) graft loss. Bruton tyrosine kinase (Btk) is required…
2017 American Transplant Congress
Evaluating Patients' Experiences Towards Their Immunosuppressive Treatment: A Way to Improve Adherence.
C. Villeneuve,^1,2 M. Grau,¹ M. Essig,^2,3 S. Hegarat,³ J. Zoughbi,³ P. Marquet,^1,2 C. Monchaud.^1,2
¹Service of Pharmacology, Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France; ²INSERM UMR850, INSERM, Limoges, France; ³Service of Nephrology, Dialysis and Transplantation, CHU Limoges, Limoges, France
In transplantation, low therapeutic adherence is associated with an increased risk of rejection, chronic allograft dysfunction and graft loss. Improving adherence necessitates identifying its barriers,…
2017 American Transplant Congress
Effects of Tofacitinib (JAK-3 Inhibitor) on De Novo HLA-A2 Antibody Production in a Mouse Model of Allo-Sensitization.
N.-N. Chai, G. Wu, I. Kim, A. Klein, S. Jordan.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose: Tofacitinib is a Janus Kinase Inhibitor currently approved by FDA for treatment of rheumatoid arthritis. In considering its effect in reducing B cell proliferation…
2017 American Transplant Congress
IL-33 Enhances the Ability of Dendritic Cells to Expand Human Regulatory T Cells.
Y. Zhao,¹ H. Zhang,¹ L. Mathews,¹ H. Turnquist,^1,2 A. Thomson.^1,2
¹Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA; ²Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Introduction:The importance of increasing the number of regulatory T cells (Treg) relative to T effectors for the promotion of long-term experimental allograft survival/tolerance is well-established.…
2017 American Transplant Congress
Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).
B. Burrell,¹ J. Bromberg,² C. Hartono,³ A. Posselt,⁴ A. Naji,⁵ D. Kaufman,⁶ R. Redfield III,⁶ S. Kanaparthi,¹ D. Ikle,⁷ K. Much,⁷ N. Bridges,⁸ L. Sun,¹ A. Priore,⁸ M. DesMarais,¹ K. Crisalli,⁹ S. Chandran,¹ J. Markmann.⁹
¹ITN, Bethesda/San Francisco; ²UMD, Baltimore; ³Rogosin, New York; ⁴UCSF, San Francisco; ⁵UPenn, Philadelphia; ⁶UWisconsin, Madison; ⁷Rho, Chapel Hill; ⁸NIAID/NIH, Bethesda; ⁹MGH, Boston
Growing evidence implicates B cells in transplant tolerance. RESTARRT is a 6-center ISW study in adult living-related-donor KTR receiving ATG induction and rituximab with a…
2017 American Transplant Congress
Single-Center, Prospective, Open Label Pilot Study to Investigate the Effectiveness of Everolimus Associated with Mycophenolic Acid and Prednisone in Adult Patients Submitted to an Allograft Renal Transplant with Calcineurin Inhibitor Withdrawl on Week 16th.
L. Giordano,^1,2 M. Lasmar,^1,2 H. Vianna,^1,2 E. Lasmar.^1,2
¹Renal Transplant Unit, Hospital Universitário Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; ²Nephrology Department, Rede Mater Dei de Saúde, Belo Horizonte, Minas Gerais, Brazil
Although CI have proven efficacy in kidney transplantation worldwide, they are drugs with nephrotoxic potential and may contribute to chronic renal allograft nephropathy. As a…